Pharmacyclics

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

Retrieved on: 
星期二, 二月 27, 2024
Biotechnology, MAIA, Gilead Sciences, Medicine, ASH, ASCO, SAB, FDA, Drug development, AbbVie, European Hematology Association, Mantle cell lymphoma, Pleasure, Kite Pharma, Hematology, EHA, University, Society, University of Bern, Patient, NK, Pharmacyclics, Acute lymphoblastic leukemia, Publication, Research, Cancer, Pharmaceutical industry

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

Key Points: 
  • CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).
  • Dr. Vezan currently serves as Vice President, Global Clinical Development at BeiGene.
  • Vezan holds vast experience in guiding oncology assets through all stages of development, from research to clinical strategies and registration.
  • Dr. Remus Vezan commented, “It is my pleasure and privilege to join MAIA as scientific advisor and support the efforts of the MAIA team in advancing the clinical development of its first-in-class telomere targeting agent.

ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment

Retrieved on: 
星期四, 十一月 2, 2023
Research, Thought Leadership, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, IPO, Pharmacyclics, Catalent, Alder, Therapy, Hematology, Nutcracker, MBS, Head, CMC, Seagen, Lundbeck, University of California, Acquisition, PTK7, Protein, Economics, Lundbeck Seattle Biopharmaceuticals, Yale University, Immunotherapy, Growth, SITC, ADC, Division, University, Biology, Amgen, Baxter International, Internal medicine, Merrill (company), Business, Keck Graduate Institute, Society for Immunotherapy of Cancer, Genentech, Society, Cancer, Seattle, University of Southern California, Coronavirus Scientific Advisory Board, Fine chemical, Management, Biochemistry, Proteolix, Chiron, Spacecraft, Western Washington University

We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.

Key Points: 
  • We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.
  • In addition, as chair of our Scientific Advisory Board, Lori brings decades of clinical thought-leadership and strategic product development experience in ADCs.
  • We look forward to working alongside them.”
    ProfoundBio also announced additional changes to the company's executive team.
  • Co-founders Tae Han and Xiao Shang will take on the roles of chief strategy officer and head of CMC, respectively.

Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer

Retrieved on: 
星期一, 十月 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Genentech, LLP, Drug development, Abstract, Harvard University, Pfizer, Data management, Drug, Pharmacyclics, Arena Pharmaceuticals, Therapy, SMMT, Quality of life, Lasso, PwC, Knowledge, Amgen, Biogen, AbbVie, Athenahealth, CFO, Stonehill College, Faculty, Risk, Jazz Pharmaceuticals, University, Cancer, Jazz, Trust, Nektar, Immunotherapy, CMO, Biostatistics, Information technology, Alnylam Pharmaceuticals, MD Anderson Cancer Center, Public health, Regulatory affairs, Nektar Therapeutics, Sale, Senior, Doctor of Philosophy, Licensed practical nurse, ARIAD Pharmaceuticals, Growth, Hematology, Patient, Management, Nursing, Pharmacovigilance, Robert Maki

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.
  • “Manmeet Soni has few peers in this industry, and his track record speaks for itself,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of Summit.
  • “Leveraging his leadership and wisdom on a daily basis is a powerful addition to the already formidable Team Summit.
  • I am grateful for the trust he has displayed in Maky, me, and our team in joining our mission full-time.”
    Mr. Soni has over 20 years of financial and operational leadership experience and joins Summit from Reata Pharmaceuticals, Inc., where he was President, Chief Operating Officer, & Chief Financial Officer.

BrainScope Receives Investment from the Alzheimer’s Drug Discovery Foundation for Alzheimer's Prediction Biomarker

Retrieved on: 
星期二, 九月 19, 2023
Research, Nursing, Medical Devices, Medical Supplies, Hospitals, FDA, Biotechnology, Health, Science, Other Science, Weil, Concussion, CT, ABS Capital Partners, IDEC, Northwell Health, General partnership, Medicine, Brain, Biomarker, BrainScope Company, Inc., Weil, Gotshal & Manges, Aria, The Manges, MRI, Traction, Patient, AbbVie, Stanford University Medical Center, Machine learning, Rituximab, Artificial intelligence, Sport, Johns Hopkins, Trauma, ALS, Ibrutinib, Computer security, Medical imaging, Pharmaceutical industry, Biogen, Pharmacyclics

Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round.

Key Points: 
  • Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round.
  • This investment supports the ongoing development of a new Artificial Intelligence / Machine Learning derived brain-activity based biomarker to predict future onset of Alzheimer’s.
  • "The global market for Alzheimer’s disease treatments is expected to rise to over $13 billion by 2030.
  • BrainScope also announced the appointment of three prominent individuals to its Board of Directors: Michael A. Epstein, Richard A. Miller MD, and Ralph Terkowitz.

Greenwave Technology Solutions Reports Third Highest Quarterly Revenues in Company History

Retrieved on: 
星期二, 八月 15, 2023
Holding, University, Metal, Harvard University, OH, Cornell Law School, Good Company (company), Harvard College, History, Pharmacyclics, Pacific Century Group, Economics, EBITDA, The Company, Intuitive Surgical, Acquisition, AbbVie, Steel, Investment, Legrand (company), Clothing, Bank, Recycling, Security (finance), Management, U.S. Steel, Greenwave

CHESAPEAKE, Va., Aug. 15, 2023 /PRNewswire/ -- Greenwave Technology Solutions, Inc. ("Greenwave" or the "Company") (NASDAQ: GWAV), a leading operator of metal recycling facilities in Virginia, North Carolina and Cleveland, OH, is pleased to announce that it generated revenues of $9.46 and $18.45 million during the three and six months ended June 30, 2023, respectively, the third highest quarterly revenues in its history. Further, for the six months ended June 30, 2023, Greenwave generated positive cashflows from operating activities of $1.23 million – a new record for the greatest amount of cashflows generated by the Company during a six month period.

Key Points: 
  • "We believe there will continue to be aggressive consolidation in this industry, as demonstrated by yesterday's buyout offer of U.S. Steel.
  • Subsequent to the close of the quarter, Greenwave commenced operation of a downstream processing system at its Kelford, NC facility.
  • Additionally, Mr. Sicignano served as General Manager at NOCO Energy Corp, as well as Vice President at Kittinger Furniture Company, Inc.
  • For more information, please see the Company's Quarterly Report on Form 10-Q filed on August 14, 2023.

Greenwave Appoints Henry Sicignano III and Jason Adelman to Board of Directors

Retrieved on: 
星期四, 八月 10, 2023
Holding, University, Harvard University, OH, Cornell Law School, Harvard College, Pacific Century Group, Pharmacyclics, Economics, The Company, Intuitive Surgical, Acquisition, AbbVie, Growth, Investment, Intuition, Management, Greenwave

CHESAPEAKE, Va., Aug. 10, 2023 /PRNewswire/ -- Greenwave Technology Solutions, Inc. ("Greenwave" or the "Company") (NASDAQ: GWAV), a leading operator of metal recycling facilities in Virginia, North Carolina and Cleveland, OH, is pleased to announce that it has appointed Henry Sicignano III and Jason Adelman to its Board of Directors.

Key Points: 
  • Jason Adelman has significant experience in corporate governance, mergers and acquisition advisory and emerging growth company investing.
  • CHESAPEAKE, Va., Aug. 10, 2023 /PRNewswire/ -- Greenwave Technology Solutions, Inc. ("Greenwave" or the "Company") (NASDAQ: GWAV), a leading operator of metal recycling facilities in Virginia, North Carolina and Cleveland, OH, is pleased to announce that it has appointed Henry Sicignano III and Jason Adelman to its Board of Directors.
  • Mr. Sicignano currently serves as the President of Charlie's Holdings, Inc., a publicly traded consumer products company with sales in more than 90 countries.
  • He currently serves on the board of directors of Kartoon Studios and served on the board of directors of Anandia Laboratories, Inc. until it was acquired in 2018.

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

Retrieved on: 
星期一, 七月 24, 2023
Science, Gilead Sciences, University, Parliamentary Information Technology Committee, AbbVie, Hematology, Non-Hodgkin lymphoma, Genentech, Pharmacyclics, Marketing, Acquisition, Patient, Celgene, Autoimmune disease, National Directorate for Migration (Argentina), Kite Pharma, Professional Football Compensation Committee, Compensated emancipation, Murray State University, Pharmaceutical industry

PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma, Inc. between 2015 and 2018, leading the worldwide commercialization effort for the CD19-CAR T cell therapy, Yescarta®, and playing a key role in its acquisition by Gilead Sciences, Inc. As part of her appointment to the Board of Directors, Ms. Tomasello will become a member of the Compensation Committee and the newly formed Science & Technology Committee.

Key Points: 
  • PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors.
  • “Shawn is a recognized biopharmaceutical leader with a proven track record building large-scale commercial organizations to bring transformative therapies to patients in need, including having overseen the global commercial launch of the leading approved CD19-CAR T cell therapy,” said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta.
  • Prior to joining Kite Pharma, she was the Chief Commercial Officer of Pharmacyclics LLC, now part of AbbVie Inc., where she led both commercial and medical affairs.
  • “I am excited to join Cabaletta’s Board of Directors and to support the company’s vision to develop and potentially launch the first targeted curative cell therapies for patients with autoimmune diseases,” said Shawn Tomasello.

Bragar Eagel & Squire, P.C. Is Investigating Viasat and BeiGene and Encourages Investors to Contact the Firm

Retrieved on: 
星期六, 七月 22, 2023
P.C, Lymphocytosis, Chronic lymphocytic leukemia, VSAT, BeiGene, Food, ABBV, Food and Drug Administration, Cancer, Pharmacyclics, Sale, Morning Star, Patent, AbbVie, News, Ibrutinib, Communications satellite, Audit, Pharmaceutical industry, Viasat, Zanubrutinib

NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viasat, Inc. (NASDAQ: VSAT) and BeiGene Ltd. (NASDAQ: BGNE).

Key Points: 
  • NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viasat, Inc. (NASDAQ: VSAT) and BeiGene Ltd. (NASDAQ: BGNE).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • The next day, BeiGene ADS’ declined by as much as $5.3, or 2.65%, in intraday trading.

Bragar Eagel & Squire, P.C. Is Investigating Castle, Coinbase, Arrival, and BeiGene and Encourages Investors to Contact the Firm

Retrieved on: 
星期一, 七月 17, 2023
P.C, Lymphocytosis, ARVL, Depression, TD, Chronic lymphocytic leukemia, Wells, BeiGene, ABBV, Food and Drug Administration, Cancer, Pharmacyclics, Electric Bond and Share Company v. Securities and Exchange Commission, Sale, Morning Star, Arrival, American Society of Clinical Oncology, Acquisition, Patent, AbbVie, Security (finance), Society, News, Ibrutinib, Food, Cryptocurrency, Audit, Zanubrutinib, Coinbase

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental health conditions.
  • The next day, BeiGene ADS’ declined by as much as $5.3, or 2.65%, in intraday trading.

Bragar Eagel & Squire, P.C. Is Investigating BeiGene and Fox and Encourages Investors to Contact the Firm

Retrieved on: 
星期二, 七月 11, 2023
News, Defamation, P.C, FOX, Lymphocytosis, Fox, Chronic lymphocytic leukemia, BeiGene, ABBV, Food and Drug Administration, Fox News, Cancer, Pharmacyclics, Sale, Government, Morning Star, United States presidential election, Fox Corporation, FOXA, Patent, AbbVie, Algorithm, Dominion, Ibrutinib, Food, Dominion Voting Systems, Pharmaceutical industry, Zanubrutinib

NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims BeiGene, Ltd. (NASDAQ: BGNE) and Fox Corp. (NASDAQ: FOX, FOXA).

Key Points: 
  • NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims BeiGene, Ltd. (NASDAQ: BGNE) and Fox Corp. (NASDAQ: FOX, FOXA).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The next day, BeiGene ADS’ declined by as much as $5.3, or 2.65%, in intraday trading.
  • For more information on the BeiGene investigation go to: https://bespc.com/cases/BGNE
    In the wake of the 2020 U.S. Presidential Election, Dominion Voting Systems sued Fox for defamation.